Effects and Central Mechanism of Electroacupuncture and MRI-navigated rTMS for PSD

Effects and Central Mechanism of Electroacupuncture and MRI-navigated rTMS for PSD: a fMRI-based Single-center, Randomized, Controlled, Assessor-blinded Trial

Introduction:

Post-stroke depression (PSD) is the most common mental complication after stroke and has a serious impact on functional outcomes and quality of life. Antidepressants are the first-line treatment for PSD, but many reported side effects remain. Clinical research and practice guidelines have shown that electro-acupuncture and rTMS have a positive effect on PSD. This trial aims to study the efficacy and safety of electro-acupuncture and a modern MRI-navigated rTMS for PSD and to explore its fMRI-based central mechanism on depression. It is hypothesized that electro-acupuncture and MRI-navigated rTMS treatment improves depressive symptoms, neuro-patho-physiological behaviors, quality of life and central response in PSD.

Methods:

In this randomized, controlled, assessors-blinded trial, sixty-four patients with PSD will be randomly allocated into the experiment group (n=32) or control group(n=32) . The experiment group will receive electro-acupuncture and MRI-navigated rTMS, and the control group will receive MRI-navigated rTMS treatment, in 12-20 sessions over 4 weeks. In addition, ten healthy people for fMRI scanning will be recruited as a healthy control group without any intervention. The primary outcome is the change from baseline in the Hamilton Depression Scale-24 items (HAMD-24) scores at week 4. The primary analysis of central mechanism mainly involves cortical morphology, local spontaneous brain activity, and default mode network (DMN) functional connectivity based on fMRI at 0-wk and 4-wk. Secondary outcomes include the neuro-patho-physiological and quality of life changes in cortical excitability with motor evoked potential test(MEP), National Institutes of Health Stroke Scale(NIHSS), EuroQol Five Dimensions Questionnaire(EQ-5D) Scale, Modified Barthel Index(MBI) Scale and Short Form-Health Scale of Traditional Chinese Medicine(SF-HSTCM). Additional indicators include the Acceptability Questionnaire and Health Economics Evaluation (cost-effectiveness analysis) to assess acceptability and economic practicality of the treatment in study. Outcomes are assessed at baseline and post intervention.

Discussion:

Electro-acupuncture and MRI-navigated rTMS therapy could become an alternative treatment for PSD, and it is expected that this trial will provide reliable clinical evidence and potential effect mechanism for the future use of electro-acupuncture and MRI-navigated rTMS for PSD.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Jiangsu
      • Nanjing, Jiangsu, China, 210008
        • Recruiting
        • Drum Tower Hospital, Medical School of Nanjing University
        • Contact:
        • Principal Investigator:
          • Hai Lu, Ph.D

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

Inclusion criteria for patients:

  • Meet the TCM and Western medicine diagnostic criteria for first onset stroke within 6 months;
  • Aged 40-75 years;
  • Right-handed;
  • Single infarct in basal ganglia (volume:3-5cm);
  • Motor evoked potential (MEP) could be recorded by bilateral primary motor cortex (M1) stimulating.
  • National Institutes of Health Stroke Scale (NIHSS) score <6;
  • Hamilton Depression Scale-24 items (HAMD-24) score > 8;
  • Clear consciousness, no hearing and visual impairment, and cooperative physical examination (Glasgow Coma Scale (GCS) score > 8);
  • Complete the screening, and sign the informed consent form voluntarily.

Inclusion criteria for healthy subjects:

  • Healthy subjects, aged 40-75 years;
  • Right-handed;
  • HAMD-24 score < 8;
  • Sign the informed consent voluntarily.

Exclusion Criteria:

Exclusion criteria for patients:

  • Have received other antidepressant therapy or involved in other clinical trials in 2 weeks;
  • Infarct was located in the left DLPFC;
  • With positive psychiatric history and major trauma exposure history, such as depression, epilepsy, etc. in the past;
  • With other serious concomitant diseases (aphasia, severe edema, venous thrombosis, arteriosclerosis occlusion, diabetic vascular disease, peripheral neuropathy, spinal lesions, brain trauma, intracranial infection, brain tumors, etc.), and secondary diseases (heart, liver, renal failure, etc.);
  • Infection around acupoints and/or intolerance of acupuncture manipulation;
  • With MRI or rTMS contraindications (claustrophobia, metal implants, cochlear implants, impulsator, etc.).

Exclusion criteria for healthy subjects:

  • Have involved in other clinical trials in 2 weeks;
  • With positive psychiatric history and major trauma exposure history, including depression, epilepsy, etc. in the past;
  • With MRI or rTMS contraindications (claustrophobia, metal implants, cochlear implants, impulsator, etc.).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experiment group
electro-acupuncture and MRI-navigated rTMS
Acupoints consist of Neiguan (PC6, bilateral), Shuigou (GV26), Sanyinjiao (SP6, affected side), Yintang (EX-HN3), Shangxing (GV23), Baihui (GV20), and Sishencong (EX-HN1). Disposable stainless-steel needles (0.25mm× 40 mm)will be used. After skin disinfection, the acupuncturists will twist and thrust the needle handles to achieve the sensation of achiness, heaviness, and numbness (known as de qi) at all acupoints. Following needle manipulations, electroacupuncture instruments(SDZ-V) will be used to attached the needle handles at EX-HN3, GV23, GV20 and EX-HN1 with a dilatational wave of 5 ~ 10 Hz and a current intensity of 1 ~ 3 mA depending on the patient's tolerance. The needles will be removed after 30 minutes except for GV26 without needle retention. Participants will receive 12-20 electroacupuncture sessions over four weeks at a frequency of 3-5 times per week.
MRI:All MRI scans were taken to acquire high-resolution T1-weighted anatomical images on the 3T MRI Scanner. Electromyography(EMG):Surface EMG was used to record MEPs from the abductor pollicis brevis for determining RMT of the non-lesioned motor cortex.A single TMS pulse was delivered to the location to identify the RMT,defined as the minimum intensity capable of evoking at least 5 MEPs of >50 μV in 10 consecutive trials.MRI-navigated rTMS:Using BrainSight system,left DLPFC targeting was individualized by reconstructing MRI data into a 3-dimensional brain image for neuro-navigation. Left DLPFC localization was central middle frontal gyrus,between superior frontal sulcus and middle frontal sulcus based on T1-weighted anatomical images.Focal rTMS was administered using a Magstim Rapid 2 connected to Y125-round coil that was identical.rTMS was applied at 110% RMT to the left DLPFC.At each session,3000 pulses were applied at 10 Hz with a total of 12-20 rTMS sessions over a 4-week period.
Active Comparator: Control group
MRI-navigated rTMS
MRI:All MRI scans were taken to acquire high-resolution T1-weighted anatomical images on the 3T MRI Scanner. Electromyography(EMG):Surface EMG was used to record MEPs from the abductor pollicis brevis for determining RMT of the non-lesioned motor cortex.A single TMS pulse was delivered to the location to identify the RMT,defined as the minimum intensity capable of evoking at least 5 MEPs of >50 μV in 10 consecutive trials.MRI-navigated rTMS:Using BrainSight system,left DLPFC targeting was individualized by reconstructing MRI data into a 3-dimensional brain image for neuro-navigation. Left DLPFC localization was central middle frontal gyrus,between superior frontal sulcus and middle frontal sulcus based on T1-weighted anatomical images.Focal rTMS was administered using a Magstim Rapid 2 connected to Y125-round coil that was identical.rTMS was applied at 110% RMT to the left DLPFC.At each session,3000 pulses were applied at 10 Hz with a total of 12-20 rTMS sessions over a 4-week period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hamilton Depression Scale-24 items scores
Time Frame: change from baseline to week 4
Reduction rate
change from baseline to week 4
fMRI scan
Time Frame: 0 week
Cortical morphology, local spontaneous brain activity, and default mode network (DMN) functional connectivity
0 week
fMRI scan
Time Frame: 4 weeks
Cortical morphology, local spontaneous brain activity, and default mode network (DMN) functional connectivity
4 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
motor evoked potential test
Time Frame: 0 week
Cortical excitability
0 week
motor evoked potential test
Time Frame: 4 weeks
Cortical excitability
4 weeks
National Institutes of Health Stroke Scale
Time Frame: 0 week
The minimum and maximum values are 0 and 42 points, and higher scores mean a worse outcome.
0 week
National Institutes of Health Stroke Scale
Time Frame: 4 weeks
The minimum and maximum values are 0 and 42 points, and higher scores mean a worse outcome.
4 weeks
EuroQol Five Dimensions Questionnaire Scale
Time Frame: 0 week
The minimum and maximum values of utility index are -0.391 and 1 points, and higher scores mean a better outcome.
0 week
EuroQol Five Dimensions Questionnaire Scale
Time Frame: 4 weeks
The minimum and maximum values of utility index are -0.391 and 1 points, and higher scores mean a better outcome.
4 weeks
Modified Barthel Index Scale
Time Frame: 0 week
The minimum and maximum values are 0 and 100 points, and higher scores mean a better outcome.
0 week
Modified Barthel Index Scale
Time Frame: 4 weeks
The minimum and maximum values are 0 and 100 points, and higher scores mean a better outcome.
4 weeks
Short Form-Health Scale of Traditional Chinese Medicine
Time Frame: 0 week
The minimum and maximum values are 0 and 130 points, and higher scores mean a worse outcome.
0 week
Short Form-Health Scale of Traditional Chinese Medicine
Time Frame: 4 weeks
The minimum and maximum values are 0 and 130 points, and higher scores mean a worse outcome.
4 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acceptability Questionnaire
Time Frame: 4 weeks
It is involved three levels: "fully accepted", "acceptable" and "not acceptable". The acceptance rate is calculated by the number of "fully accepted" and "acceptable" subjects. And higher rate mean a better outcome.
4 weeks
Health Economics Evaluation
Time Frame: 4 weeks
Cost-effectiveness analysis
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 22, 2022

Primary Completion (Anticipated)

June 30, 2025

Study Completion (Anticipated)

August 1, 2025

Study Registration Dates

First Submitted

August 15, 2022

First Submitted That Met QC Criteria

August 24, 2022

First Posted (Actual)

August 25, 2022

Study Record Updates

Last Update Posted (Actual)

March 23, 2023

Last Update Submitted That Met QC Criteria

March 22, 2023

Last Verified

August 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022-LCYJ-PY-08

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD sharing will be made during the 6 months after the end of study, and the original data can be obtained from the PI if necessary.

IPD Sharing Time Frame

During the 6 months after the end of study.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on electro-acupuncture

3
Subscribe